Luna Innovations INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OTC.Pink
Ernst & Young LLP resigned as Luna Innovations' auditor due to concerns over the company's financial reporting and internal controls, as well as the company's plan to deregister its common stock.
OTC.Pink
8-K: Luna Innovations Announces Delisting from Nasdaq and Provides Preliminary 2024 Financial Results
Luna Innovations plans to delist from Nasdaq and deregister its stock, while also reporting improved financial performance in the second half of 2024.
OTC.Pink
Luna Innovations will be delisted from the Nasdaq Stock Market due to its inability to meet filing deadlines, and its shares will transition to the OTC Markets.
OTC.Pink
Pamela Coe has resigned from the Luna Innovations Board of Directors, effective December 27, 2024, due to her retirement.
OTC.Pink
Luna Innovations has received another notice from Nasdaq for failing to file its quarterly reports, putting its listing status at risk.
OTC.Pink
Luna Innovations has amended its loan agreement to secure an additional $15 million in funding and has also entered into an agreement with preferred stock holders.
OTC.Pink
Luna Innovations has appointed William L. Phelan as its new Chief Financial Officer and Chief Accounting Officer, succeeding John C. Roiko who is retiring.
OTC.Pink
Luna Innovations has received a delisting notice from Nasdaq due to its failure to file required financial reports, and the company plans to appeal the decision.
OTC.Pink
Luna Innovations has received a third notice from Nasdaq for failing to file its financial reports, putting its listing status at risk.
OTC.Pink
Luna Innovations has entered into a $15 million loan agreement and appointed Kevin Ilcisin as its new President and CEO, effective August 1, 2024.
OTC.Pink
Luna Innovations Incorporated reports the resignation of its Interim Executive Chairman due to health reasons and the appointment of a new non-executive Board Chair.
OTC.Pink
Luna Innovations has received an extension from Nasdaq to file its overdue financial reports by September 11, 2024, but faces potential delisting if it fails to meet this deadline.
OTC.Pink
Luna Innovations has received a notice from Nasdaq regarding its failure to file required financial reports, putting its listing status at risk.
OTC.Pink
Luna Innovations has appointed a new CFO, engaged strategic advisors, initiated a strategic review, and provided an update on its ongoing financial review.
OTC.Pink
8-K: Luna Innovations to Restate Multiple Years of Financial Statements Due to Revenue Recognition Errors
Luna Innovations has announced it will restate its financial statements for 2022 and interim periods through March 31, 2023, due to accounting errors related to revenue recognition.
OTC.Pink
Luna Innovations has received a notice from Nasdaq for failing to file its annual report on time, putting its listing status at risk.
OTC.Pink
Luna Innovations has appointed Richard Roedel as Interim Executive Chairman and President following the retirement of Scott Graeff, initiating a search for a new CEO.
OTC.Pink
Luna Innovations has determined that its financial statements for the second and third quarters of 2023 should no longer be relied upon due to revenue recognition issues identified during an independent review.